China’s Home-Grown Oral COVID Antiviral Eyes Wider Population
Simcere Kicks Off Phase I
Simcere is weighing options for SIM0417 in a Phase I trial in China as the first major domestically-developed potential rival to Pfizer’s oral COVID-19 antiviral Paxlovid. The study is likely to include wider patient groups ranging from those without symptoms to severe patients.
You may also be interested in...
Top-line results for two newly approved COVID-19 antivirals in China showed roughly 1.5- to two-day cuts in median time to symptom resolution or recovery in mild-to-moderate Omicron patients versus placebo.
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.